Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 3 chart positions in 3 markets.
By chart position
- 🇺🇸US · Life Sciences#1725K to 30K
- 🇫🇮FI · Life Sciences#603K to 10K
- 🇹🇷TR · Life Sciences#153500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
4.3K to 22K🎙 Weekly cadence·16 episodes·Last published 5mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
8.5K to 43K🇺🇸70%🇫🇮23%🇹🇷7% - Active Followers
Loyal subscribers who consistently listen
2.5K to 13K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
DMPK Insights #16: HR-LC/MS: A Key Consideration for Environmental Fate and Plant/Livestock Metabolism Studies
Dec 8, 2025
31m 29s
DMPK Insights #15: Pharmacokinetics-Pharmacodynamics: Driving decision making with PKPD throughout Drug Discovery
Aug 28, 2025
42m 13s
DMPK Insights #14: Evolution of CNS Drug Disposition Models
Aug 1, 2025
32m 03s
DMPK Insights #13: The Influence of QSAR and Physicochemical Descriptors on Drug Design: A Brief History and New Paradigms
Jun 26, 2025
37m 25s
DMPK Insights #12: New Frontiers in Understanding the BBB Transport of Small Molecule Drugs
Apr 24, 2025
38m 41s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 12/8/25 |  DMPK Insights #16: HR-LC/MS: A Key Consideration for Environmental Fate and Plant/Livestock Metabolism Studies | For a captioned and video version or to access the transcript and ask a question for our experts about this podcast episode, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-16-metabolism-studies/#cprtstatus=_cp_0!channel!AAIDoxPJjQQe In this special episode of the Pharmaron DMPK Insights Podcast Series, our experts explore the critical role of metabolism studies in agrochemical research. The discussion focuses on metabolite identification and its importance in determi... | 31m 29s | ||||||
| 8/28/25 |  DMPK Insights #15: Pharmacokinetics-Pharmacodynamics: Driving decision making with PKPD throughout Drug Discovery | For a captioned version or to access the transcript and ask a question for our experts about this podcast episode, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-15-pkpd-drug-discovery/ In this episode of the Pharmaron DMPK Insights Podcast Series, Simon Taylor and Dr. Emile Chen discuss the relationship of drug concentration and effect (PKPD). PKPD is critical to decision making from initial modality selection, through molecule optimization, translational science and... | 42m 13s | ||||||
| 8/1/25 |  DMPK Insights #14: Evolution of CNS Drug Disposition Models | For a captioned version or to access the transcript, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-14-cns-modelling/ In this podcast, Scott Summerfield and Professor Elizabeth de Lange discuss the evolution of CNS drug disposition models, highlighting the increasing sophistication of physiologically based pharmacokinetic (PBPK) models, such as LeiCNS-PK3.0. They discuss how these tools are enhancing our understanding of CNS drug distribution, predicting human pharmaco... | 32m 03s | ||||||
| 6/26/25 |  DMPK Insights #13: The Influence of QSAR and Physicochemical Descriptors on Drug Design: A Brief History and New Paradigms | For a captioned version or to access the transcript, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-13-qsar-physicochemical-descriptors/ In this podcast, Scott Summerfield and Matt Segall will discuss QSAR and how in silico ADME science has evolved to influence Drug Design and improve the ADME properties of hit and lead compounds. We will address the following questions: What were the drivers for the emergence of QSAR and Phys Chem Descriptors?Today’s state-of-... | 37m 25s | ||||||
| 4/24/25 |  DMPK Insights #12: New Frontiers in Understanding the BBB Transport of Small Molecule Drugs | For a captioned version or to access the transcript, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-12-bbb-transporters/ In this podcast, Elena and Mikko will discuss the current state-of-the-art around transporter sub-types and their expression within the blood-brain barrier (BBB) and opportunities for utilizing these transporters for brain drug delivery. We will address the following questions: Current knowledge of BBB transporters in health and disease&n... | 38m 41s | ||||||
| 3/18/25 |  DMPK Insights #11: Drug Meets Bug: How the Gut Microbiome Shapes DMPK | For a captioned version or to access the transcript, please visit https://www.pharmaron.com/knowledge-center/dmpk-podcast-11-gut-microbiome/. In this podcast, Chris Bode (Pharmaron US Labs) interviews Peter Turnbaugh, a microbiologist and Professor of Microbiology and Immunology at the University of California San Francisco. Over the past 15-20 years, Peter has produced so much groundbreaking research in the endlessly fascinating field of the gut microbiome. His work is not limited to DMPK by... | 47m 27s | ||||||
| 1/15/25 |  DMPK Insights #10: The DMPK Project Representative: An essential role of contribution, integration and evolution | In this podcast Simon Taylor (Pharmaron UK) interviews Kevin Beaumont, a highly experienced DMPK scientist, leader and drug developer who has lived and breathed the role of the DMPK Project Representative throughout his 40-year industrial career. With experience of delivering clinical drug candidates across multiple therapeutic areas with two major pharma companies (Pfizer and AstraZeneca) Kevin describes his entry into the role, the value of people, in roles as mentee and mentor, and t... | 47m 36s | ||||||
| 8/12/24 |  DMPK Insights #9: 60 and Beyond: Navigating the Frontiers of PBPK and QSP | In this podcast, listeners will join us in celebrating the remarkable career of Professor Amin Rostami, a trailblazer in the realms of PBPK and QSP. Following his 60th birthday, Professor Rostami will provide insights into his journey, the dynamic evolution of PBPK and QSP, and the exciting horizons ahead. Tune in for a deep dive into the intersections of academia and industry, technological advancements, and the invaluable lessons garnered throughout a pioneering career. The episode explore... | 39m 32s | ||||||
| 7/8/24 |  DMPK Insights #8: It’s “All-go” with Oligos: Challenges and Opportunities in LC-MS of Therapeutic | In this podcast, Robert MacNeill, Professor Michael Bartlett of the University of Georgia and Dr. Guilherme Guimaraes of Biogen, will focus on oligonucleotide LC-MS covering the exciting key challenges, the pivotal nature of sensitivity in such assays, and the various analytical approaches and technologies that have been used, currently in use or being developed. The episode explores the following: How recent liquid chromatographic and mass spectral innovations have impacted the bioana... | 27m 04s | ||||||
| 5/10/24 |  DMPK Insights #7: Carboxylic Acids and DILI – Conjugation and Reputation | In this podcast, Professor Ian Wilson, a globally recognised and leading expert in drug metabolism, with over 500 publications in the field, takes us on an engaging journey exploring the link between carboxylic acid containing drugs and their involvement in DILI. A special focus will be given to Ian’s latest paper: ‘Minimizing the DILI potential of carboxylic acid-containing drugs: a perspective’. The episode explores the following: Are acyl glucuronides shouldering too much of the blame?Whe... | 33m 32s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 3/6/24 |  DMPK Insights #6: Protein Mass Spectrometry: Advancing the Bioanalysis of Biotherapeutics and Biomarkers | In this podcast, Scott and John will discuss the LC-MS techniques that have been applied for the bioanalysis of biotherapeutics. The episode explores the following: The impact that mass spectrometry is having in the biotherapeutics and biomarker spaceThe rationale behind the use of LC-MS for certain biomarkers and how sensitive LC-MS assays can be developed (and the practical limits for lower limits of quantification that can be achieved)Developments in mass spectrometry that are expected t... | 39m 33s | ||||||
| 12/14/23 |  DMPK Insights #4: DMPK Past, Present and Future – A Festive Tale | This podcast format is inspired by the Charles Dicken’s novella “A Christmas Carol” whereby Phil Jeffrey (Bicycle Therapeutics), Beth Williamson (UCB) and Daniel Price (Nimbus) discuss DMPK Past, Present and Future with Scott. Key elements discussed include the evolution of DMPK as a predictive discipline that links helps the chemistry of drug design with the biology of drug disposition and effect. The episode addresses the following questions: The founding names and principles of DMPK ... | 1h 03m 36s | ||||||
| 9/21/23 |  DMPK Insights #5: Mass Spectrometry Imaging - Past, Present and Future | In this podcast, Josephine Bunch, Principal Research Scientist and Co-Director of the National Centre of Excellence in Mass Spectrometry (NiCE-MSI) at NPL, talks about her work, and in particular her involvement in the Cancer Research UK Grand Challenge Programme. The episode explores the following: Recent innovations in MSI Challenges associated with analyzing ever more complex moleculesLabel-free vs labelled imagingHardware and software improvements and how these affect t... | 30m 38s | ||||||
| 9/18/23 |  DMPK Insights #3: Free Drug Theory: No Longer Just a Hypothesis? | In this podcast, Scott Summerfield, Senior Director, Pharmaceutical Metabolism at Pharmaron discusses his recent publication on Free Drug Theory (FDT) with Simon including the principles, arguments, and project impact. This article was an invited contribution to a special edition of the Pharmaceutical Research Journal recognizing the achievements of Professor Margareta Hammarlund-Udenaes and Kp,uu. The episode addresses the following questions: What is the FDT?How FDT relates to fundamental p... | 36m 15s | ||||||
| 9/17/23 |  DMPK Insights #2: Pathways to Successful Drug Design – Discovery Metabolite ID | In this podcast, Dan Weston, Scientific Leader, Biotransformation at GSK discusses his recent publication on the important role that Metabolite ID plays in drug discovery. The episode addresses the following questions: Why studying biotransformation is an important part of early drug design A strategy to combine in silico tools, high-resolution MS and software-assisted data analysis to optimize data delivery and qualityHow this influences medicinal chemistry and the design–make–test cycl... | 26m 43s | ||||||
| 9/12/23 |  DMPK Insights #1: Candidate Survival – 3 Pillars to 5Rs and Beyond | In this podcast, Dr. Paul Morgan, Head of DMPK at Grünenthal Group, discusses the development of the publication that introduced the “5R framework” and improved the likelihood of AstraZeneca candidate survival from candidate drug nomination to Phase III. We will then discuss how the area has developed since then and where the field may go in the future. The episode addresses the following questions: What was the situation like that led to the development of the 5Rs?How was the analysis conduc... | 45m 41s | ||||||
Showing 16 of 16
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
3 placements across 3 markets.
Chart Positions
3 placements across 3 markets.